Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 346 (8966), 26-8

Treatment of HIV-associated Kaposi's Sarcoma With Paclitaxel

Affiliations
Clinical Trial

Treatment of HIV-associated Kaposi's Sarcoma With Paclitaxel

M W Saville et al. Lancet.

Abstract

We investigated whether paclitaxel was active in AIDS-associated Kaposi's sarcoma. We gave 135 mg/m2 intravenously over 3 hours every 21 days. Follow-up is available on the first 20 patients, most of whom had advanced Kaposi's sarcoma and severe immunocompromise. Neutropenia was the most frequent dose-limiting toxic effect; novel toxic effects included late fevers, rash, and eosinophilia. Creatinine increased in 2 patients and 1 patient had cardiomyopathy. There were 13 partial responses (65%, 95% CI 41-85%). All 5 patients with pulmonary involvement responded. Paclitaxel appears to be active against Kaposi's sarcoma as a single agent. Further studies, including a randomised trial, are warranted.

Similar articles

See all similar articles

Cited by 16 PubMed Central articles

See all "Cited by" articles

Publication types

Feedback